Brain Stimulation
October 28, 2020
K. Fox, Josef Parvizi
BACKGROUND Brain stimulation, both invasive and non-invasive, is increasingly being used to modulate mood and other aspects of subjective experience in various neuropsychiatric conditions. Because this enterprise is deeply dependent on first-person reports provided by patients, sham stimulation is routinely employed to control for demand characteristics and placebo effects. However, a general...
Frontiers in Psychiatry
October 22, 2020
Felix Müller, Markus Mühlhauser, Friederike Holze et al.
31 citations
A 39-year-old female patient suffering from severe, treatment-resistant depression and other symptoms associated with a complex personality disorder was admitted to our open psychiatric ward for an experimental treatment with lysergic acid diethylamide (LSD). The substance was administered in repeated weekly and ascending doses. Curiously, there were no substantial acute subjective effects of...
Neuropsychopharmacology
October 15, 2020
Friederike Holze, Patrick Vizeli, Laura Ley et al.
243 citations
Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25...
arXiv Preprint Archive
October 13, 2020
Caroline Lahogue, Didier Pinault
preprint
Running title: Frontoparietal anodal tDCS reduces ketamine-induced oscillopathies.Abstract: During the prodromal phase of schizophrenia with its complex and insidious clinical picture, electroencephalographic recordings detect widespread oscillation disturbances (or oscillopathies). Neural oscillations are electro-biomarkers of the connectivity state within systems. A single systemic...
Journal of Psychopharmacology
October 8, 2020
Yasmin Schmid, Peter Gasser, Peter Oehen et al.
82 citations
Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re-investigated as treatments for several psychiatric disorders. In Switzerland, limited medical use of these substances is possible in patients not responding to other treatments (compassionate use). Methods: This study aimed to...
Journal of Extreme Anthropology
October 6, 2020
Sagit Mezamer
In July 2018 we met at the airport, my brother and I. We were bound for Portugal, where my brother was about to undergo treatment for his heroin addiction. A visual essay following an Ibogaine treatment. By artist and curator, Sagit Mezamer The imagery in this essay is taken from drawings and photographs from Mezamer's new artwork - The Mother of Opium.
Revista Peruana de Medicina Integrativa
October 6, 2020
Edison Chávez Castillo, Cynthia Chávez Castillo, Jorge Zuquitana Godoyc
2 citations
La ayahuasca es un brebaje psicotrópico con acción serotoninérgica. Las fuentes botánicas más comunes de la ayahuasca son la Banisteriopsiscaapi y la Psychotriaviridis, en la revisión bibliográfica se buscó conocer las propiedades bioquímicas, síntomas y signos que produce esta planta, asimismo, se reconocieron los efectos que produce al ser utilizada como brebaje por los chamanes de la...
October 5, 2020
M. Taheri, Farid Semsarha, Majid Mahdavi et al.
preprint
Mohammad Ali Taheri, the inventor of Faradarmani method believes beyond matter and energy fields, there are consciousness fields that can be accessed through connection of the consciousness of the subject of study to the cosmic consciousness network. This causes an optimization in a subject’s structure and function. Apart from the fact that most studies in the field of cancer are aimed at the...
Journal of Translational Medicine
October 2, 2020
Lara Sharpe, Justin Sinclair, Andrew Kramer et al.
122 citations
BACKGROUND: -tetrahydrocannabinol (THC) has been associated with an anxiogenic response, while anxiolytic activity has been attributed mainly to cannabidiol (CBD). In animal studies, the effects of THC are highly dose-dependent, and biphasic effects of cannabinoids on anxiety-related responses have been extensively documented. A more precise assessment is required of both the anxiolytic and...
International Journal of Molecular Sciences
October 1, 2020
M. Bowman, Melissa Vitela, K. Clarke et al.
Major depressive disorder is typically treated with selective serotonin reuptake inhibitors (SSRIs), however, SSRIs take approximately six weeks to produce therapeutic effects, if any. Not surprisingly, there has been great interest in findings that low doses of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, produce rapid and long-lasting antidepressant effects....